Host-directed therapies for tuberculosis: quantitative systems pharmacology approaches.
Trends Pharmacol Sci
; 43(4): 293-304, 2022 04.
Article
in En
| MEDLINE
| ID: mdl-34916092
ABSTRACT
Host-directed therapies (HDTs) that modulate host-pathogen interactions offer an innovative strategy to combat Mycobacterium tuberculosis (Mtb) infections. When combined with tuberculosis (TB) antibiotics, HDTs could contribute to improving treatment outcomes, reducing treatment duration, and preventing resistance development. Translation of the interplay of host-pathogen interactions leveraged by HDTs towards therapeutic outcomes in patients is challenging. Quantitative understanding of the multifaceted nature of the host-pathogen interactions is vital to rationally design HDT strategies. Here, we (i) provide an overview of key Mtb host-pathogen interactions as basis for HDT strategies; and (ii) discuss the components and utility of quantitative systems pharmacology (QSP) models to inform HDT strategies. QSP models can be used to identify and optimize treatment targets, to facilitate preclinical to human translation, and to design combination treatment strategies.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Tuberculosis
/
Mycobacterium tuberculosis
Limits:
Humans
Language:
En
Journal:
Trends Pharmacol Sci
Year:
2022
Document type:
Article
Affiliation country: